Skip to contentA
Anika Therapeutics, Inc.
A
ANIKAnika Therapeutics, Inc. Q2 2013 · 10-Q
Revenue$20.83M$20.83M+6.1% vs Q2 2012 Net Income$5.89M$5.89M+57.7% vs Q2 2012 EPS Diluted$0.40$0.40+53.8% vs Q2 2012 Gross Profit$13,756,075+27.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
Operating Cash Flowderived$3,564,072−31.8% Free Cash Flowderived$3,490,003−18.9% Margins · derivedGross margin66.0%+11.0 pt vs Q2 2012
Operating margin45.1%+13.9 pt vs Q2 2012
Net margin28.3%+9.3 pt vs Q2 2012
ended Jun 30, 2013 · filed Aug 6, 2013 · 37 d after period end